On November 11, 2026, Google DeepMind announced AlphaGenome 2, a new AI model that predicts how changes in DNA affect specific human cell types. It is a research tool, not a hospital product, but it shows clearly where AI in medicine is heading: from answering questions to reading the body's most fundamental code. For Indian healthcare businesses, healthtech startups and researchers, this is a development worth understanding.
What AlphaGenome 2 actually does
Every cell in your body carries the same DNA, but each cell type reads it differently. A heart muscle cell switches on different genes than an immune cell fighting an infection. Many diseases begin when a small DNA variation, called a variant, changes how a gene behaves in one specific cell type.
DeepMind's first AlphaGenome, launched last year, predicted how variants affect molecular activity across broad tissues. A follow-up platform, AlphaGenome Atlas, extended those predictions to all 9 billion possible single-letter changes in the human genome. AlphaGenome 2 goes further: instead of broad tissue averages, it predicts effects inside individual cell types and cell states. DeepMind says it was trained on more than 107 million individual cell profiles across 68 tissues, and it can predict effects in cell states it has never seen, such as cells responding to a disease or a vaccine.
The results DeepMind reported
On the TenK10K dataset, a large single-cell map of 28 immune cell types, AlphaGenome 2 identified nearly twice as many causal variants as the original model fine-tuned on single-cell data (30% versus 16%), and nearly twice as many directional gene effects (43% versus 23%). In plain terms, it spots far more of the DNA changes that actually switch genes on or off in a given cell type, and whether they push activity up or down.
The model also reproduced a known medical finding computationally. Researchers had shown that a variant in a distant regulatory switch drives inflammatory bowel disease by overactivating a gene called ETS2 in gut immune cells called macrophages. Making predictions across immune cell types in the gut, AlphaGenome 2 singled out the same variant and showed that it boosts ETS2 selectively in those macrophages, leaving other cell types and genes largely unaffected.
In another test, DeepMind gave the model single-cell data from a COVID-19 mRNA vaccine study it had not been trained on. AlphaGenome 2 distinguished vaccine-activated immune T cells from resting ones, and showed that a variant linked to severe COVID-19 disrupts gene activity more strongly in the activated state. That is an effect older, tissue-level models would miss.
Why this matters for India
Three reasons stand out.
First, disease burden. DeepMind reports that the model's precomputed variant scores help pinpoint the specific variants and cell types most likely to be involved in complex traits ranging from height to type 2 diabetes. India carries one of the world's largest diabetes burdens, so tools that connect genetic variants to the cells where disease unfolds are directly relevant to research on conditions affecting tens of millions of Indians.
Second, access. AlphaGenome 2 is available for non-commercial research through the AlphaGenome API, with commercial use in private preview. Indian universities, research institutes and public health programmes can start working with it now, which lowers the barrier for serious genomics research outside wealthy private labs.
Third, the signal for healthtech. AI in healthcare is moving beyond documentation assistants and chatbots into core biological research. The tools being built today will shape diagnostics and drug discovery over the next several years. Indian healthtech companies that understand this shift early will be better placed when clinical-grade versions arrive.
The important caveat
DeepMind is explicit: AlphaGenome and AlphaGenome 2 are intended for research use only and have not been validated or approved for clinical or diagnostic purposes. No hospital or clinic should use this to make decisions about patients. It is research infrastructure, not a product to buy or deploy. If any vendor implies otherwise, treat the claim with caution.
What healthcare businesses should take away
For most Indian healthcare organisations, the practical AI opportunity today remains unglamorous: automating front-desk workflows, patient follow-ups, billing, reports and engagement. That is where returns are real and immediate.
But AlphaGenome 2 is a reminder that AI's role in medicine is deepening quickly. Organisations that get their data, systems and digital workflows in order now will be ready to adopt clinical-grade AI as it matures. Those that wait will face a steeper climb.
If you want to understand where AI can deliver value in your healthcare business today, VAIR IT offers a free consultation. We build practical software for healthcare and other industries, and we will tell you honestly what is worth doing now and what can wait.
